The Journal of Clinical Psychopharmacology Podcast

Mar 04 2025 54 ep. 13 mins 37
The Journal of Clinical Psychopharmacology Podcast artwork

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

  Health & Fitness
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Growing Concerns Over Valproate Teratogenicity Present an Opportunity for Lithium

Mar 04 2025 21 mins  
Valproic acid is one of the most frequently prescribed mood-stabilizing agents for bipolar disorder, and in some regions of the world, it now competes with lithium as the preferred treatment of choice for bipolar maintenance. There may soon be restrictions on the use of valproic acid, however, because of the risk in neural tube defects and major congenital malformations in children

Clinical Management of Designer Benzodiazepine Intoxication: A Systematic Review

Mar 04 2025 10 mins  
"Designer benzodiazepines" are lab-created chemical derivatives of prescription benzodiazepines. They have not been approved for medical use and there is limited information on their safety and toxicity. More potent than their prescription counterparts, this subset of novel psychoactive substances have been growing in popularity in recent years and pose the potential for dangerous

At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy)

Mar 04 2025 12 mins  
Dr. Donald C. Goff, Marvin Stern professor of psychiatry at NYU Grossman School of Medicine, gives an overview of a new combination drug recently approved by the U.S. Food and Drug Administration for the treatment of schizophrenia. It will be marketed as Cobenfy, and its component active ingredients are xanomeline and trospium chloride, representing the first non-dopaminergic antip

Ethics in Psychedelic Science: Promises and Responsibilities

Jan 06 2025 32 mins  
Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest editorial “Ethics in Psychedelic Science: Promises and Responsibilities” with its author, Dominic Sisti, PhD, a medical ethicist from the Perelman School of Medicine at the University of Pennsylvania, and a JCP podcast panel of E

Broad-Spectrum Micronutrients or Antidepressants for Antenatal Depression: Effect on Maternal and Infant Birth Outcomes in an Observational Secondary Analysis of NUTRIMUM

Jan 06 2025 27 mins  
About 20% of women experience depression while they are pregnant, and untreated depression has been associated with increased rates of adverse birth outcomes and complications. In this podcast, Julia J. Rucklidge, PhD, of the University of Canterbury in Christchurch, New Zealand, discusses nutrition, pregnancy, and mental health in detail with psychiatrist and Journal of Clinical

Psychopharmacologic Laziness

Oct 25 2024 13 mins  
Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of Journal of Clinical Psychopharmacology (JCP), discusses the editorial “Psychopharmacologic Laziness” with its author, Dr. Anthony Rothschild, who is Editor-in-Chief of JCP. He contends that psychotropic medications with well-established efficacy for the treatment of various psychiatric conditions are underprescrib

Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States

Oct 25 2024 6 mins  
According to the US Centers for Disease Control and Prevention, products containing psychoactive compounds such as cannabis or mushroom extracts are increasing in availability though they may have undisclosed ingredients, contaminants, and adulterants. Elisa Nguyen, and Drs. Abraham Qavi and Minh-Ha Tran, authors of the letter to the editor “Health Alert: Microdose Products Lea

Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty

Oct 25 2024 14 mins  
This podcast features Dr. Chadi Calarge, a child psychiatrist at Baylor College of Medicine and, for over 20 years, a researcher focused on long-term psychiatric medication safety with regard to height growth and metabolic abnormalities. He gives an overview of past and forward-looking research questions related to growth, growth hormones, and such drugs as selective serotonin reu

Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges

Aug 26 2024 7 mins  
Ketamine and esketamine represent significant advancements for patients with treatment-resistant depression. Their rapid action provides much needed relief for patients who do not respond to traditional antidepressants. Their use, however, introduces challenges that necessitate ongoing research and careful consideration to maximize their potential, which Dr. Balwinder Singh, MD, MS

High-dose propranolol for severe and chronic aggression in autism spectrum disorder

Aug 26 2024 12 mins  
The symptoms of irritability associated with autism spectrum disorder (ASD) include aggression, tantrums, self-injury, and disruption. Propranolol, a beta-blocker, has accumulated much anecdotal evidence as a promising option for symptoms of these disorders, but well-designed studies are rare. Dr. Eric London is the lead author of the article “High-dose propranolol for severe and